---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-001905"
form_type: "8-K"
ticker: "AIM"
cik: "0000946644"
company_name: "AIM ImmunoTech Inc."
filed_at: "2024-01-10T23:59:59+00:00"
generated_at: "2026-06-07T01:13:21.398471+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# AIM ImmunoTech opens enrollment in Phase 1b/2 trial of Ampligen + Imfinzi for pancreatic cancer

## Summary
- Enrollment open at Erasmus MC for DURIPANC study combining Ampligen + AstraZeneca's Imfinzi; dosing expected soon.
- Phase 1b portion will enroll up to 18 subjects; Phase 2 up to 25 patients with metastatic pancreatic ductal adenocarcinoma.
- Ampligen dose escalation from 200 mg to 400 mg IV twice weekly; durvalumab 1500 mg IV every 4 weeks for up to 48 weeks.
- Primary objectives: safety in Phase 1b, clinical benefit rate in Phase 2.
- AIM recently received a U.S. patent for using Ampligen in combination with an anti-PD-L1 antibody.

## SEC filing metadata
- accession: 0001493152-24-001905
- form_type: 8-K
- ticker: AIM
- cik: 0000946644
- company_name: AIM ImmunoTech Inc.
- filed_at: 2024-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946644/000149315224001905/0001493152-24-001905-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946644/000149315224001905/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-001905
- JSON: https://secwatch.observer/filing/0001493152-24-001905.json
- Plain text: https://secwatch.observer/filing/0001493152-24-001905.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.